RECURSION PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
RECURSION PHARMACEUTICALS, INC. (RXRX) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $21.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2021-11-10
- 2021-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $21.00K.
- 2021-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.03M.
- 2021-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.05M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2021-09-30 | $21.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.03M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $1.05M 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |